7-[4-(4-Methyl-piperazin-1-yl)-piperidin-1-yl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-ylamine → N-[(1R,2R)-2-(5-Chloro-2-{7-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-ylamino]-pyrimidin-4-ylamino)-cyclohexyl}-methanesulfonamide
Reaction equation
[CH3:1][N:2]1[CH2:7][CH2:6][N:5]([CH:8]2[CH2:13][CH2:12][N:11]([CH:14]3[CH2:20][CH2:19][C:18]4[CH:21]=[C:22]([NH2:25])[CH:23]=[CH:24][C:17]=4[CH2:16][CH2:15]3)[CH2:10][CH2:9]2)[CH2:4][CH2:3]1.Cl[C:27]1[N:32]=[C:31]([NH:33][CH:34]2[CH2:39][CH2:38][CH2:37][CH2:36][CH:35]2[NH:40][S:41]([CH3:44])(=[O:43])=[O:42])[C:30]([Cl:45])=[CH:29][N:28]=1>>[Cl:45][C:30]1[C:31]([NH:33][C@@H:34]2[CH2:39][CH2:38][CH2:37][CH2:36][C@H:35]2[NH:40][S:41]([CH3:44])(=[O:43])=[O:42])=[N:32][C:27]([NH:25][C:22]2[CH:23]=[CH:24][C:17]3[CH2:16][CH2:15][CH:14]([N:11]4[CH2:12][CH2:13][CH:8]([N:5]5[CH2:4][CH2:3][N:2]([CH3:1])[CH2:7][CH2:6]5)[CH2:9][CH2:10]4)[CH2:20][CH2:19][C:18]=3[CH:21]=2)=[N:28][CH:29]=1Participants
3
Reactant 2
Product 1
Procedure
The title compound was prepared from 7-[4-(4-Methyl-piperazin-1-yl)-piperidin-1-yl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-2-ylamine and N-[2-(2,5-Dichloro-pyrimidin-4-ylamino)-cyclohexyl]-methanesulfonamide in an analogous manner to Example 179 heating at 140° C. Product was isolated as an off-white solid (10 mg, 9%). LCMS (m/e) 645 (M+1); 1H NMR (400 MHz, DMSO-d6) δ 9.32 (m, 2H), 7.97 (s, 1H), 7.57 (m, 1H), 7.42 (m, 1H), 7.17 (m, 1H), 7.06 (d, 1H, J=7.8 Hz), 6.95 (m, 1H), 3.38-2.82 (m, 8H), 2.94-3.02 (m, 8H), 2.67-2.77 (m, 8H), 2.33 (m, 2H), 1.95-2.06 (m, 4H), 1.72 (m, 4H), 1.15-1.44 (m, 8H).
Sources & evidence
- ORD record
- ord-42e12fd380f14b2bb2dfc519cbd7097c
- Source dataset
- uspto-grants-2013_10
- Patent number
- US08552186B2
Reaction notes
Loading…